COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
ORANO (France)
Inventeur(s)
Billy, Emmanuel
Porthault, Helene
Abrégé
A method for opening an electrochemical generator (10) comprising a negative electrode (20) containing lithium or sodium and a positive electrode (30) optionally containing lithium or sodium, the method comprising the following successive steps: a) immersing the electrochemical generator (10) in a solution comprising an inert liquid and, optionally, a redox species, referred to as an oxidising redox species, capable of being reduced on the negative electrode so as to discharge the electrochemical generator; b) opening the electrochemical generator in the solution with a cutting element (100) that has an electrical resistance between 1 m? and 1 k?, and preferably between 5 m? and 100 ?.
H01M 6/52 - Récupération des parties utiles des éléments ou batteries usagés
H01M 8/008 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Élimination ou recyclage des éléments à combustible
2.
METHOD FOR DISSOLVING A POSITIVE ELECTRODE MATERIAL
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
ORANO (France)
Inventeur(s)
Billy, Emmanuel
Abrégé
The invention relates to a method for dissolving a positive electrode material of a battery comprising a step during which the positive electrode material, comprising lithium and optionally cobalt and/or nickel, is submerged in an acid solution having a pH between 0 and 4, the acid solution containing either manganese ions or hydrogen peroxide, by means of which the lithium and optionally the cobalt and/or nickel is dissolved, and the manganese ions are selectively precipitated in the form of manganese oxyhydroxide.
The invention relates to a PSMA-targeting conjugate or a pharmaceutically acceptable salt which may be used either for preparing a radiopharmaceutical or, once labeled with a radionuclide, as a radiopharmaceutical. The conjugate is of formula (I): A1-L1-Ch -L2-A2 (I) wherein: Ch is a chelator, L1 and L2, identical or different, are a linker whereas A1 and A2, identical or different, are an urea-based PSMA ligand. The invention also relates to the uses thereof.
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
ORANO (France)
Inventeur(s)
Billy, Emmanuel
Abrégé
The invention relates to a method for securing an electrochemical generator (10) comprising a negative electrode (20) containing lithium or sodium and a positive electrode (30), the method comprising the following successive steps: (a)immersing an electrochemical generator (10) in an ionic liquid solution (100) containing a solvent ionic liquid and, optionally, a redox species, referred to as the oxidising species, capable of being reduced on the negative electrode so as to discharge the electrochemical generator; (b) opening the electrochemical generator with an electrically insulative element, opening being performed in the ionic liquid solution.
H01M 10/054 - Accumulateurs à insertion ou intercalation de métaux autres que le lithium, p.ex. au magnésium ou à l'aluminium
C22B 7/00 - Mise en œuvre de matériaux autres que des minerais, p.ex. des rognures, pour produire des métaux non ferreux ou leurs composés
H01M 4/02 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif
H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
The invention relates to a conjugate or a pharmaceutically acceptable salt thereof, the conjugate being of formula: C-L-A, wherein C is a chelator, L is a linker covalently bound to the chelator and A is a Gastrin-releasing peptide receptor antagonist covalently bound to the linker, characterized in that: - the chelator is of formula (I): where the dotted line represents the covalent bond to the linker; - the linker is of formula: -?-Ala-?-Ala-; and - the Gastrin-releasing peptide receptor antagonist has the amino acid sequence: -DPhe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2. The invention also relates to the uses of the conjugate or salt thereof.
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
ORANO (France)
Inventeur(s)
Billy, Emmanuel
Barthelemy, Sandrine
Abrégé
Disclosed is a method for selectively separating a carbon-containing material from a mixture comprising a positive electrode and a negative electrode originating from fuel cells and/or electrochemical batteries, the method comprising the following successive steps: a) providing a mixture comprising a positive electrode and a negative electrode, each electrode comprising a current collector, an active material and a binder, the active material of the negative electrode being a carbon-containing material, preferably graphite, b) bringing the mixture comprising the positive electrode and the negative electrode into contact with a separating solution, in the presence of ultrasound, the separating solution comprising a solvent and possibly additives, until the carbon-containing material is selectively separated from the current collector of the negative electrode, the active material of the positive electrode remaining joined to the current collector of the positive electrode.
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
ORANO (France)
Inventeur(s)
Billy, Emmanuel
Abrégé
Disclosed is a method for recycling at least one electrode, comprising the following consecutive steps: a) providing at least one electrode comprising a current collector, an active material and, optionally, a binder, b) immersing the at least one electrode in an ionic liquid solution comprising a solvent ionic liquid, in the presence of ultrasound, whereby the active material, and if applicable the binder, is separated from the current collector.
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
8.
PROCESS FOR SITE-SPECIFIC MODIFICATION OF AN ANTIBODY
The present application concerns a process for preparing a site-specific bioconjugated antibody with a metal Chelator, the bionconjugated antibody and its use in nuclear medicine.
The invention relates to a method for preparing one or more generators with a high radium-228 content from an aqueous solution comprising thorium-232 and radium-228. The generator(s) can be used, in particular, for producing thorium-228, from which radium-224, then lead-212 and bismuth-212 can be obtained. The method and the generator(s) that it can be used to prepare are therefore applicable, in particular, in the manufacture of radiopharmaceuticals made from lead-212 or bismuth-212, which can be used in nuclear medicine and, in particular, in targeted alpha radiotherapy for the treatment of cancers.
The invention relates to a method for transferring a radioisotope that is attached to a first stationary phase contained in a first chromatography column to a second stationary phase contained in a second chromatography column, in order to fix the radioisotope to the second stationary phase, wherein the radioisotope is selected from the radioactive isotopes of thorium, radium, lead, bismuth and uranium. Said method comprises at least the following steps: a) eluting the radioisotope from the first stationary phase with an aqueous solution A1 comprising an agent complexing the radioisotope, whereby an aqueous solution A2 is obtained which comprises complexes of the radioisotope; b) dissociating the complexes of the radioisotope present in the aqueous solution A2 by modifying the pH of the aqueous solution A2, whereby an aqueous solution A3 comprising the decomplexed radioisotope is obtained; c) loading the second stationary phase with the aqueous solution A3; and d) carrying out at least one washing of the second stationary phase with an aqueous solution A4.
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p.ex. production d'isotopes radioactifs
G21G 4/08 - Sources radioactives autres que les sources de neutrons caractérisées par des aspects de leur structure spécialement adaptées aux applications médicales
11.
METHOD FOR PRODUCING LEAD-212 FROM AN AQUEOUS SOLUTION COMPRISING THORIUM-228 AND ITS DESCENDANTS
The invention relates to a method for producing x-ray very high purity lead-212 from an aqueous solution comprising thorium-228 and its descendants. Applications: manufacture of radiopharmaceuticals based on lead-212, which are useful in nuclear medicine and, in particular, in targeted alpha radiation therapy for the treatment of cancers.
C22B 3/24 - Traitement ou purification de solutions, p.ex. de solutions obtenues par lixiviation par des procédés physiques, p.ex. par filtration, par des moyens magnétiques par adsorption sur des substances solides, p.ex. par extraction avec des résines solides
A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrogen ring structure including a tetraazacyclododecane, a triazacyclononane, and/or a tetraazabicyclo [6.6.2] hexadecane derivative. The targeting moiety includes a somatostatin receptor targeting peptide. The somatostatin receptor targeting peptide includes an octreotide derivative. The targeting moiety is chelated to the radioisotope by the chelator whereby the cancer cells are targeted for elimination.
The present invention concerns a process for producing a daughter radionuclide from a parent radionuclide comprising the purification of the daughter radionuclide on a chromatography column, as well as the apparatus for carrying out such process.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p.ex. production d'isotopes radioactifs
brevets
